Drug Trial Radar · NCT00004846
Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV
Last checked: Nov 19, 2026Latest source record: Mar 4, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30,000
Actual
Start
Dec 1999
Primary completion
Not stated
Study completion Oct 2002
Sponsor
- Lead sponsor
- National Institutes of Health Clinical Center (CC)NIH
- Sponsor type
- NIH
- First posted
- Mar 3, 2000
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the accuracy of an experimental test method called nucleic acid amplification technology (NAT) in detecting human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This test amplifies the nucleic acid in a virus more than a million-fold, allowing early detection of minute quantities of virus in the blood. Blood donors to the National Institutes of Health's Department of Transfusion Medicine (blood bank) will have their blood screened with transcription mediated amplification, a type of NAT test. Donors whose blood is found positive for HIV or HCV by NAT testing will be notified and asked to participate in this study. Those who agree will provide a blood sample about once a week for 3 months. The samples will be tested with additional assays to detect evidence of HIV or HCV infection. If the test results are confirmed positive, no more blood samples will be collected. The results of the tests and their significance will be explained to participants. It is anticipated that NAT screening will reduce the risk of transfusion-related HIV transmission from the current 1 in 650,000 to 1 in a million and the risk of HCV transmission from the current 1 in 100,000 to 1 in 350,000. It is possible that these tests will completely eliminate the risk of transmitting these diseases through blood transfusion.
Conditions
- Hepatitis C
- HIV Infection
Interventions
ABC/Gen-Probe/Chiron HIV-1/HCV 001Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.